L. F. Verdonck

P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.

E. D. de Vries, E. Vellenga, G. Ossenkoppele, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

E. Vellenga, M. Fey, M. Jongen‐Lavrencic, 2014, Leukemia.

Guanidinoacetate methyltransferase deficiency

S. Berkovic, D. Timson, J. Thoden, 2020, Definitions.

Immunophenotyping of non-Hodgkin's lymphoma. Correlation with relapse-free survival.

H. Schuurman, L. Verdonck, J. van Unnik, 1988, The American journal of pathology.

Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology.

H. Schuurman, L. Verdonck, J. van Unnik, 1987, The American journal of pathology.

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

W. M. Smit, M. Kersten, P. Sonneveld, 2008, Blood.

A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies.

A. Hagenbeek, W. V. van Solinge, A. Buijs, 2001, Blood.

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

P. Sonneveld, B. van der Holt, G. Ossenkoppele, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of serum levels on leukemic cell destruction by the ether lipid ET-18-OCH3.

L. Verdonck, G. Rijksen, E. C. Heesbeen, 1995, Leukemia research.